Travere Therapeutics (TVTX) Tops Q2 EPS by 14c

Travere Therapeutics (NASDAQ: TVTX) reported Q2 EPS of ($0.65), $0.14 better than the analyst estimate of ($0.79). Revenue for the quarter came in at $54.12 million versus the consensus estimate of $50.4 million.

For earnings history and earnings-related data on Travere Therapeutics (TVTX) click here.

You May Also Be Interested In

• PG&E Corp, Edison spike on chatter
• Action Behavior Centers' Family Advocacy Team Meets with Congressional Leaders in Washington, D.C., to Discuss Access to ABA Therapy for Autism
• U.S. House passes stopgap funding bill to avoid government shutdown